朗姿股份有限公司 2024 年度内部控制自我评价报告 朗姿股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合朗姿股份有限公司（以下简称 "公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上， 我们对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性 进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰 ...

关于本报告 报告简介 本报告是朗姿股份有限公司发布的第四份《环境、社会及管治（ESG） 报告》。报告本着客观、规范、透明和全面的原则，详细披露了 2024 年 朗姿在环境保护、社会责任、公司治理等领域的实践和绩效。 时间范围 本报告的时间范围是 2024 年 1 月 1 日至 2024 年 12 月 31 日，为增 强报告的可比性和完整性，部分内容超出上述范围。 报告范围 本报告以朗姿股份为主体，涵盖朗姿股份及其全资子公司、控股子公司， 除特别说明外，本报告范围与本公司的财务报告合并报表范围保持一致。 参考标准 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》《深圳证券交易所上市公司自律监管指引第 17 号——可持续发 展报告（试行）》（以下简称"《指引》"）《深圳证券交易所上市公 司自律监管指南第 3 号——可持续发展报告编制》《中国企业可持续发 展报告指南 CASS-ESG6.0_ 一般框架》全球报告倡议组织《GRI Standard 2021》联合国可持续发展目标（SDGs）等。 指代说明 为了便于表述和阅读，本报告中称谓指代如下： | 简称 | 全称 / 业务板块 | | - ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 朗姿股份有限公司（以下简称"朗姿股份"或"公司"）于2025年4月2日召开第 五届董事会第二十九次会议审议通过了《关于续聘2025年度审计机构的议案》。 同意续聘立信会计师事务所（特殊普通合伙）（以下简称"立信"）为公司2025年 度财务审计机构和内部控制审计机构，并同意将本议案提交公司股东大会审议。 同时，公司董事会提请股东大会授权公司管理层根据2025年度财务报告审计及内 控审计的范围和要求与立信协商确定相关审计费用并签署相关协议。 现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （3）组织形式：特殊普通合伙企业 （4）注册地址：上海市黄浦区南京东路61号四楼 证券代码：002612 证券简称：朗姿股份 公告编号：2025-012 朗姿股份有限公司 关于拟续聘会计师事务所的公告 （5）首席合伙人：朱建弟 （6）人员信息：截至2024年末，立信拥有合伙人296名、注册会计师2,498 名、从业人员总数10,021名，签署过证券服务业务审计报告的注册会计师743 名。 （7 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-017 朗姿股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 朗姿股份有限公司（以下简称"公司"）于 2025 年 4 月 2 日召开第五届董事 会第二十九次会议，审议通过了《关于召开 2024 年度股东大会的议案》。本次 股东大会审议的议案具体内容已披露在《证券时报》《上海证券报》《中国证券 报》和巨潮资讯网（www.cninfo.com.cn）。同时，公司独立董事将在本次年度股 东大会上进行述职。 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会。 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董事 会第二十九次会议审议决定召开。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025年4月25日下午14:00时。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年4月2 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-009 朗姿股份有限公司 第五届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届监事会第十三次 会议通知于 2025 年 3 月 28 日以专人送达、电子邮件等方式发出，并于 2025 年 4 月 2 日以通讯及现场会议方式召开。会议由监事会主席李婷女士主持，会议应 出席监事 3 名，实际出席监事 3 名，公司董事会秘书王建优先生列席本次会议。 会议的召集和召开符合《中华人民共和国公司法》《朗姿股份有限公司章程》和 《朗姿股份有限公司监事会议事规则》等有关规定，会议合法有效。 二、监事会会议审议情况 1、审议并通过了《2024 年度监事会工作报告》 公司《2024年度监事会工作报告》具体内容详见公司同日刊登在巨潮资讯网 （www.cninfo.com.cn）上的公告。 本议案尚需提交公司2024年度股东大会审议。 表决结果：同意3票，反对0票，弃权0票。 2、审议并通过了公司《2024 年年 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-008 朗姿股份有限公司 第五届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第二十九 次会议通知于 2025 年 3 月 28 日以邮件、专人送达等通知方式发出，经 5 位董事 一致同意，于 2025 年 4 月 2 日以通讯及现场会议方式召开。会议由董事长申东 日先生主持，会议应出席董事 5 人，实际出席 5 人。公司监事会及高级管理人员 列席了本次会议。本次会议的召开符合《中华人民共和国公司法》《朗姿股份有 限公司章程》《朗姿股份有限公司董事会议事规则》的有关规定，合法有效。 二、董事会会议审议情况 1、审议并通过了公司《2024 年年度报告》及《2024 年年度报告摘要》 董事会认为：公司《2024 年年度报告》及《2024 年年度报告摘要》符合法 律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 ...

Financial Performance - The company's total revenue for the reporting period reached ¥2,688,923,889.57, representing a year-on-year increase of 6.21% compared to ¥2,531,716,988.59 in the previous year[163]. - The company's operating revenue for the current reporting period is ¥2,688,923,889.57, representing a year-on-year increase of 6.21% compared to ¥2,531,716,988.59 in the previous year[19]. - The net profit attributable to shareholders for the current period is ¥151,743,006.58, which is a 1.14% increase from ¥150,029,576.83 in the same period last year[19]. - The net profit after deducting non-recurring gains and losses is ¥139,923,796.82, reflecting an increase of 11.49% compared to ¥125,500,391.91 in the previous year[19]. - The medical beauty business segment achieved revenue of 1,194.48 million yuan, a year-on-year increase of 6.02%, with a gross profit of 647.78 million yuan and a gross margin of 54.23%[113]. - The fashion women's wear segment generated ¥1,012,460,789.19, accounting for 37.65% of total revenue, with a growth of 11.41% from ¥908,738,157.17 in the previous year[164]. - The medical beauty segment contributed ¥1,194,484,638.99, which is 44.42% of total revenue, showing a growth of 6.02% from ¥1,126,697,847.08 in the previous year[164]. - The revenue from the women's tops category was ¥291,224,463.25, showing a 10.58% increase year-over-year, with a gross margin of 65.15%[168]. - The revenue from the children's clothing segment was ¥331,071,392.38, representing a 16.09% increase year-over-year, with a gross margin of 63.53%[168]. - The company achieved a high pass rate of 98% in its medical safety knowledge examination, with a participation rate of 99% among frontline staff[117]. Market Position and Strategy - The company operates in the textile and apparel industry, classified under "C18 Textile, Apparel, and Accessories" according to national economic industry classification standards[4]. - The company has established a multi-industry interconnected ecosystem, focusing on fashion women's wear, medical beauty, and green infant and child products[43]. - The company aims to create a "pan-fashion industry interconnected ecosystem" by leveraging its strengths in women's fashion, medical beauty, and green baby and children’s sectors[144]. - The company is focusing on high-end markets and has made refined adjustments to its product offerings to better reach the younger consumer demographic[84]. - The company is committed to continuous innovation in products and services to meet the evolving needs of beauty seekers[99]. - The company has a clear strategy for future growth, emphasizing the integration of fashion and medical beauty sectors[150]. Operational Efficiency and Risk Management - The company emphasizes the importance of risk awareness in its forward-looking statements regarding future development plans and operational strategies[4]. - The company has detailed its potential operational risks and corresponding countermeasures in the report[4]. - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[4]. - The company has implemented a digitalization strategy, including RFID technology to enhance supply chain management and improve operational efficiency in stores[85]. - The company is leveraging data analytics to drive business decisions, having established a data warehouse and improved reporting capabilities to monitor operational performance[87]. - The company has established a comprehensive CRM system to boost member sales and loyalty, significantly increasing member value and purchase conversion rates[86]. Brand Development and Marketing - The company is enhancing brand power by promoting the new brand core concept "Bringing Love and Power to the World," aiming to resonate with consumers and elevate brand recognition[77]. - The brand LɅNCY targets urban elite women aged 25-45, emphasizing quality and material, and aims to empower women through its fashion offerings[44]. - The MOJO brand is strengthening its core product identity through a comprehensive marketing matrix involving brand ambassadors and KOLs to enhance consumer engagement[78]. - The LIME brand is actively shaping its image through collaborations with celebrities and KOLs, enhancing its presence on social media and overall exposure[79]. - The company has upgraded its store designs to enhance customer experience and brand recognition, creating an inviting atmosphere for consumers[83]. - The company has established a total of 92 in-house fashion designers and has no contracted designers[186]. Medical Beauty Sector Growth - The medical beauty industry in China is projected to grow at an annual rate of 10% to 15% over the next four years, driven by increasing disposable income and social acceptance[35]. - The company has successfully expanded its medical beauty business, acquiring 38 medical beauty institutions, including 9 comprehensive hospitals and 29 clinics as of the end of the reporting period[91]. - The company aims to become an industry leader by accelerating its national layout of medical beauty services, with recent acquisitions including Zhengzhou Jimei in Q1 2024[91]. - The company has established seven medical beauty acquisition funds with a total scale of 2.837 billion yuan to enhance its business scale and resource integration[117]. - The company emphasizes safety and quality in its medical services, with the Sichuan Milan hospital recognized as a 5A-level beauty hospital by the China Association of Plastic Surgery[94]. - The company has received multiple certifications and honors, including "5A Level Medical Beauty Hospital" and "TÜV-SQS Medical Service Quality Management System Certification" for its facilities[109]. Consumer Trends and Demographics - The global consumer market is shifting towards emerging markets, with a focus on younger generations, retirees, and the middle class, indicating a growing willingness to explore alternative brands[30]. - 64% of consumers prioritize spiritual consumption, highlighting the increasing importance of cultural identity and emotional value in purchasing decisions[32]. - In 2023, China's population decreased by 2.08 million, with a birth rate of 6.39‰, indicating a continued decline in birth rates and natural population growth[33]. - Despite a declining birth rate, the children's clothing market is experiencing growth, with children's running shoes sales doubling year-on-year and other categories seeing over 30% growth[34]. Investment and Financial Health - The company holds a 26.53% stake in Agabang & Company, a KOSDAQ listed company in South Korea[11]. - The company has a 9.56% shareholding in Guangzhou Ruoyuchen Technology Co., Ltd. as of the end of the reporting period[11]. - Cash and cash equivalents increased to 591,303,557, representing 7.79% of total assets, up from 5.69% at the end of the previous year[195]. - Short-term borrowings rose to 1,005,507.42, which is 13.24% of total liabilities, an increase of 4.15% compared to the previous year[195]. - Investment income amounted to 19,012,554.73, accounting for 8.56% of total profit, indicating sustainable earnings from joint ventures and financial investments[194].

Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on a total of 442,445,375 shares[4]. Risk Awareness and Forward-Looking Statements - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report, highlighting potential risks in future development[3]. Business Operations and Investments - The company has established a chain brand "Jingfu Medical Beauty," which operates 30 medical beauty institutions and 5 beauty stores across various cities[9]. - The company holds a 10% stake in Guangzhou Ruoyuchen Technology Co., Ltd., which is publicly listed[9]. - The company has a 29.23% stake in Beijing Lanzi Hanya Asset Management Co., Ltd., a significant investment in asset management[9]. - The company is involved in multiple investment partnerships, including a 49.88% stake in Wuhu Bochen No. 5 Equity Investment Partnership[10]. - The company has a 46.91% stake in Wuhu Boheng No. 2 Venture Capital Partnership, indicating active participation in venture capital[10]. - The company has a 19.96% stake in Chengdu Lanzi Wufa Medical Beauty Industry Equity Investment Fund, showcasing its investment strategy in the medical beauty sector[10]. Financial Performance - The company's operating revenue for 2024 was CNY 5,690,786,090, a decrease of 0.24% compared to CNY 5,704,641,390 in 2023[17]. - The net profit attributable to shareholders for 2024 was CNY 257,202,654, reflecting an increase of 1.38% from CNY 253,693,995 in 2023[17]. - The net cash flow from operating activities decreased by 35.61% to CNY 566,585,643 in 2024, down from CNY 879,894,753 in 2023[17]. - Basic earnings per share for 2024 were CNY 0.5813, up 1.38% from CNY 0.5734 in 2023[17]. - Total assets at the end of 2024 were CNY 7,971,411,120, a decrease of 4.68% from CNY 8,362,546,130 at the end of 2023[18]. - The company reported a weighted average return on equity of 7.86% for 2024, an increase of 0.80% from 7.06% in 2023[17]. - The company recognized government subsidies of CNY 23,248,705.60 in 2024, compared to CNY 17,539,879.09 in 2023[23]. - The company disposed of non-current assets resulting in a loss of CNY 691,566.59 in 2024, down from a gain of CNY 13,796,216.90 in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 217,630,692, an increase of 11.30% compared to CNY 195,530,732 in 2023[17]. - The company experienced a significant decline in net assets attributable to shareholders, which decreased by 21.59% to CNY 2,787,342,997 at the end of 2024 from CNY 3,555,028,550 at the end of 2023[18]. Market Trends and Economic Indicators - In 2024, the retail sales of clothing in China reached CNY 1,071.62 billion, with a year-on-year growth of only 0.1%, indicating a slowdown in growth[30]. - Fixed asset investment in the clothing industry increased by 18.0% year-on-year in 2024, surpassing the overall growth rates of the textile and manufacturing sectors by 2.4 and 8.8 percentage points respectively[30]. - The per capita clothing consumption expenditure for residents in 2024 was CNY 1,521, reflecting a growth of 2.8% compared to the previous year[28]. - The contribution rate of domestic demand to economic growth in 2024 was 69.7%, highlighting its role as the main driver of economic growth[29]. - The number of newborns in China in 2024 was 9.54 million, an increase of 520,000 from 2023, marking the first rise since 2017[35]. - The online retail sales of physical goods in 2024 reached CNY 1,308.16 billion, growing by 6.5% year-on-year, accounting for 26.8% of total retail sales[27]. - The growth of per capita expenditure on other goods and services was 10.8% in 2024, with rural residents seeing a 12.8% increase[28]. - The government is implementing policies to boost consumption, including increasing pensions and improving employment opportunities, which are expected to enhance consumer spending[29]. - The clothing industry is experiencing a recovery in investment confidence, with a focus on smart production and brand development to improve supply chain efficiency[30]. - The rise of the "she economy" is changing consumer behavior, with women increasingly prioritizing personalized and quality consumption[33]. - The maternal and infant market in China reached a consumption scale of 4 trillion yuan in 2023, with an expected growth rate of around 7% in the future[36]. - In the children's clothing sector, 70% of parents continue to invest in their children's outfits, indicating a strong consumer willingness across different family types[37]. Medical Beauty Industry Insights - The number of plastic surgeons in China has reached 3,000, ranking fourth globally, highlighting the rapid growth of the medical beauty industry[38]. - The genuine product rate of medical beauty injectables in the market is only 35%, emphasizing the need for improved consumer education and regulatory oversight[38]. - By 2025, Hangzhou aims for a revenue target of 5-8 billion yuan in the medical beauty industry, with a dual policy approach to support and regulate the sector[42]. - Chengdu has set a target for its medical beauty industry to exceed 100 billion yuan by 2025, with ongoing initiatives to enhance industry standards and consumer protection[42]. - The overall medical beauty market in China is projected to grow at a rate of approximately 10% in 2024, with a compound annual growth rate of 10-15% expected from 2024 to 2027[43]. - The current market penetration rate of medical beauty services in China is only 4-5%, indicating significant growth potential compared to countries like the US and South Korea[44]. - The introduction of 14 new Class III injectable products and over 60 optical medical devices in early 2024 reflects a rich supply-side growth in the medical beauty sector[44]. - The trend of "self-care" consumption is emerging, with consumers increasingly valuing the positive impacts of medical beauty on their well-being[44]. Women's Apparel Segment Performance - The women's apparel segment achieved revenue of 192,506.01 million yuan, a decrease of 2.97% compared to the previous year, with a gross profit of 122,153.83 million yuan and a gross margin of 63.45%[63]. - The total number of women's apparel stores at the end of the reporting period was 522, including 366 self-operated stores, 99 franchised stores, and 57 online stores, a decrease of 77 stores from the previous year[62]. - Online sales accounted for 39.94% of the women's apparel revenue, increasing from 37.25% in the previous year, while self-operated sales represented 55.08%[65]. - The LɅNCY brand generated 142,784.13 million yuan, making up 74.17% of the women's apparel revenue, showing a slight increase from 71.55% in the previous year[64]. - The LIME brand contributed 33,945.45 million yuan, accounting for 17.63% of the women's apparel revenue, down from 19.14% in the previous year[64]. - The company operates a dual business model for women's apparel, focusing on self-operated and franchised stores while expanding online channels[62]. - The company emphasizes a "sales-driven production" model, optimizing inventory levels and turnover times[63]. - The women's apparel segment's revenue from self-operated stores was 106,035.34 million yuan, representing 55.08% of total revenue[65]. - The company has established a multi-industry interconnected fashion ecosystem, focusing on women's fashion, medical beauty, and green children's products[63]. - The company aims to maintain its industry-leading position by enhancing its digital operations and marketing capabilities[63]. E-commerce and Digital Operations - The company's e-commerce payment amount for the entire year of 2024 increased by over 19% year-on-year, with Tmall channel payment amount growing by 7% and Douyin channel payment amount increasing by over 37%[76]. - During the 2024 Double 11 event, the total e-commerce payment exceeded 597 million, representing a 34% year-on-year growth, with Tmall's single store payment reaching 369 million, achieving a 49% year-on-year increase[76]. - The company participated in the WHO'S NEXT fashion exhibition in Paris, showcasing the unique charm of MADE IN CHINA to the global fashion industry[66]. - The company established a comprehensive customer management system integrating public and private domain operations, enhancing brand visibility on platforms like Xiaohongshu and Douyin[75]. - The company implemented RFID technology to enhance inventory management accuracy and operational efficiency across stores, achieving real-time alignment of accounts and inventory[72]. - The company launched a new product line targeting urban women's diverse scenarios, including business commuting, high-end social events, and outdoor activities, while prioritizing eco-friendly materials[68]. - The company organized over three high-frequency offline store activities monthly to enhance customer engagement and improve in-store conversion rates[69]. - The company's video account on Douyin achieved over 13.45 million views and 340,000 interactions in 2024, while Xiaohongshu garnered 3.63 million views and added 18,000 new followers[75]. - The company is focusing on enhancing brand perception through a multi-dimensional visual material output system, significantly increasing the frequency of brand content delivery[67]. - The company is optimizing its product development and ordering systems to improve efficiency and reduce costs, ensuring accurate and consistent product information across all channels[73]. Medical Beauty Business Expansion - The company has successfully expanded its medical beauty business, acquiring 41 medical beauty institutions, including 12 comprehensive hospitals and 29 clinics, as of the end of the reporting period[77]. - In 2024, the company continued its expansion by acquiring Zhengzhou Jimei, Beijing Milan, and Hunan Yamei, further enhancing its market presence[77]. - The company has achieved TUV-SQS medical quality service system certification for 8 medical beauty institutions and 5A hospital qualification for 5 institutions, including Xi'an Milan and Beijing Milan[78]. - The company’s flagship brand, Milan Baiyu, has transitioned to a nationwide chain model, with significant upgrades in locations such as Shenzhen and Beijing[79]. - The company’s subsidiary, Jingfu Medical Beauty, has established 30 hospitals and clinics, focusing on community-based services and lifestyle beauty solutions[91]. - The company’s Kunming Hanchen hospital, established in 2015, spans approximately 12,000 square meters and features 20 hotel-standard patient rooms and 11 advanced operating rooms[93]. - Wuhan Hanchen, established in 2015, has over 6,000 square meters of renovated space and has passed the TUV-SQS certification in 2023[95]. - The company emphasizes a dual-driven model of external expansion and internal growth, enhancing its operational efficiency and market reach[77]. - The company aims to become a benchmark for standardized and healthy development in the medical beauty industry in China[79]. - The company has implemented strict operational standards, including a seven-day cooling-off period and real-time video monitoring, to protect customer rights[91]. Medical Beauty Segment Financials - The medical beauty business segment achieved revenue of 2,783.87 million yuan, a year-on-year increase of 3.47%[109]. - The gross profit for the medical beauty segment was 1,514.87 million yuan, with a gross margin of 54.42%[109]. - The main revenue sources by brand include Milan Baiyu at 1,265.26 million yuan (45.44%), Crystal Skin Medical Beauty at 470.95 million yuan (16.92%), and Han Chen Medical Beauty at 369.37 million yuan (13.27%) for the year 2024[112]. - Non-surgical medical beauty services accounted for 85.58% of total medical beauty revenue, while surgical services made up 14.42%[113]. - The company has established seven medical beauty acquisition funds with a total scale of 2.837 billion yuan to enhance its market position[114]. - The company aims to integrate and absorb high-quality domestic medical beauty resources to rapidly capture market share through brand promotion and chain operations[114]. Certifications and Standards - The company has received multiple certifications and awards, including "AAAAA Level Medical Beauty Institution" and "5A Level Medical Beauty Hospital"[100][102]. - The company is committed to the principles of "safe medical beauty, quality medical beauty, and reputable medical beauty" to ensure compliance and enhance industry standards[114]. - The company plans to continue developing its strategic planning to support the long-term growth of its medical beauty business[114]. Safety and Quality Initiatives - In 2024, the company organized 305 emergency drills, including 253 major event drills and 52 CPR drills, covering a total of 4,885 participants[116]. - The company launched 35 new quality standards for medical aesthetics services, focusing on customer feedback and service quality improvement[120]. - The company's digital platform integrates various modules, enhancing customer experience and operational efficiency through data analysis and management[119]. - The company continues to enhance its medical safety standards, conducting quarterly assessments and training sessions to ensure compliance with safety regulations[116]. Green Baby and Children's Business Performance - The company's green baby and children’s business generated revenue of 921.49 million yuan, a decrease of 5.53% year-over-year, with a gross profit of 569.08 million yuan and a gross margin of 61.76%[128]. - The total revenue from the infant and child business reached ¥92,149.35 million, a decrease of 5.4% from ¥97,545.53 million in 2023[129]. - Agabang accounted for 51.53% of the infant and child business revenue in 2024, down from 48.81% in 2023, while Ettoi represented 32.68%, slightly decreasing from 33.15%[129]. - The company added 14 new stores in the infant and child business during the reporting period, bringing the total to 545 stores[130]. - Self-operated sales contributed ¥72,308.99 million, representing 78.47% of the total infant and child revenue in 2024, compared to 75.94% in 2023[131]. - The company is focusing on enhancing its high-end brand "ETTOI" in the domestic market, aiming to increase sales and brand influence through various promotional activities[132]. Research and Development - The company has established a strong digital operation capability, utilizing AI, RFID, and BI tools to enhance efficiency across product development, sales strategies, and inventory management[138]. - The R&D center has obtained 7 invention patents and 24 software copyrights, indicating a strong commitment to product innovation and development[140]. - The company has a strategic focus on building a "pan-fashion industry interconnected ecosystem," targeting the fashion women's, medical beauty, and green infant and child sectors[133]. - The company is leveraging its digital platform to improve customer relationship management and operational efficiency in the medical beauty sector[139]. Cash Flow and Financial Management - Operating cash inflow decreased by 1.19% to ¥5,815,099,390.05, while cash outflow increased by 4.87% to ¥5,248,513,746.51, resulting in a net cash flow decrease of 35.61%[187]. - Investment cash inflow surged by 216.67% to ¥1,156,970,660.01, primarily due to increased recovery of financial products[188]. - Investment cash outflow rose by 107.92% to ¥1,573,791,282.37, attributed to higher acquisition payments and financial product transactions[188]. - Financing cash inflow increased by 11.51% to ¥1,984,045,753.78, while outflow decreased by 9.98% to ¥2,050,554,092.87, leading to a net cash flow improvement of 86.66%[188]. - The net increase in cash and cash equivalents rose significantly by 686.91% to ¥61,612,958.96, driven by improved financing cash flow[189]. Product Development and Innovation - The company aims to enhance product functionality and competitiveness through new patent applications, including a detachable sleeve for protective jackets[184]. - The company is focusing on expanding its product line with innovative designs, such as a high-neck sweater and a women's garment with an adjustable waist[184]. - The company is committed to improving the practicality and aesthetics of its clothing products, thereby increasing market competitiveness[184]. Investment and Acquisitions - The company reported a significant increase in total investments during the reporting period, totaling 1,573,791,282.37, a 107.92% increase compared to the previous year's investment of 756,929,474.75[197]. - The company completed a significant acquisition of a medical beauty hospital for a total investment of 920 million, representing a 100% ownership stake[198]. - The company also acquired another medical beauty hospital for 330 million, maintaining a 100% ownership stake[198]. - A third acquisition involved a medical beauty hospital for 252 million, also achieving 100% ownership[198]. - The total amount of equity investments made during the reporting period reached 751.92 million[198]. Financial Assets and Liabilities - The company’s total financial assets at the end of the reporting period were valued at 632.05 million[200]. - The company has ongoing non-equity investments, although specific details were not disclosed[199]. - The company’s securities investments included a public fund with a cost of 186 million and a fair value of 119.7 million, resulting in a loss of 19.98 million[200]. - The company reported a fair value change of 37.52 million for its financial asset investments, with a total investment of 792.25 million[200].

Group 1 - The board of directors of Langzi Co., Ltd. held its 28th meeting of the 5th session on March 24, 2025, to discuss and approve various matters [1][2] - The meeting approved a proposal for joint investment with related parties to accelerate the national layout strategy of the company's medical beauty business [1][2] - The proposal involves the establishment of employee stock ownership platforms to enhance the performance of subsidiaries and incentivize key employees in the medical beauty sector [1][2] Group 2 - The employee stock ownership platforms are structured entities controlled by the company and included in the consolidated financial statements [2] - The independent directors held a special meeting and unanimously agreed to the proposal, with one related director abstaining from the vote [2] - The voting results were 4 in favor, 0 against, and 0 abstentions [2]

证券代码：002612 证券简称：朗姿股份 公告编号：2025-007 朗姿股份有限公司 关于与关联人共同投资暨关联交易的公告 本公司及董事会全体人员保证公告信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、本次交易概述 为了加快落地朗姿股份有限公司（以下简称"公司"或"朗姿股份"）医美 业务的全国布局战略，充分调动管理层和医美业务板块主要骨干员工的积极性， 建立与企业共享、共担的长效激励和约束机制，提升子公司的经营业绩，公司全 资子公司朗姿医疗管理有限公司（以下简称"朗姿医管"）自 2017 年 7 月以来 先后通过成都姿韵企业管理咨询合伙企业（有限合伙）（以下简称"成都姿韵"）、 成都韵甜企业管理咨询合伙企业（有限合伙）（以下简称"成都韵甜"）、成都 姿衡企业管理咨询合伙企业（有限合伙）（以下简称"成都姿衡"）、成都翔丹 企业管理咨询合伙企业（有限合伙）（以下简称"成都翔丹"）、成都爱咪企业 管理咨询合伙企业（有限合伙）（以下简称"成都爱咪"）等 11 个员工持股平 台，与部分管理层和医美板块主要骨干员工共同投资新设或新进医美机构，并由 朗姿医管担任上述员工持股平台的普通合伙人 ...